Skip to main content
pharmacist medication patient hero

PQS Trend Report examines socio-demographic, utilization factors related to medication adherence

This year’s report underscores the impact that socio-demographic factors could have on performance.
Levy

Pharmacy Quality Solutions, a provider of performance management services, released its 2023 Industry Trend Report in Pharmacy Quality. This year’s report underscores the impact that socio-demographic factors could have on performance, further supporting the need for tailored patient solutions utilizing pharmacy to drive positive changes. 

In the first chapter, the trend report focuses on the impact of socio-demographic factors, including age, gender and low-income subsidy status, on adherence rates for cholesterol, diabetes and renin angiotensin system antagonists proportion of days covered measures. 

Andrew Thorne, director of analytics and program development at PQS, highlighted that across all three PDC measures, performance tends to be slightly lower for patients who are eligible for low-income subsidy. “Our findings suggest that economic status may have a more pronounced impact than variables such as age and gender,” Thorne said.

[Read more: PQS launches next-generation EQUIPP platform]

The next chapter of the report highlights how adherence can be impacted by factors such as drug switching within a measurement year and the utilization of extended fills. Extended fill utilization had the most noteworthy difference for the Diabetes PDC measure, where there is a performance rate difference exceeding 20% between extended fill and only non-extended fill scenarios. 

Beyond these insights, the 2023 Trend Report underscores the importance of medication adherence and the methods used for its measurement. By presenting a review of the performance differences in medication adherence, PQS aims to empower quality stakeholders and advocates with the knowledge to enhance medication quality and ultimately, patient health outcomes. 

To download the trend report to access the full insights, please visit here

X
This ad will auto-close in 10 seconds